Indication: For the treatment of schizophrenia and manic episodes associated with bipolar disorder. Not indicated for maintenance treatment.
Brand name: Seroquel.
Regulatory status: Marketed January 2004 for bipolar disease.
Launch date: Marketed January 2004 for bipolar disease.